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Iron deficiency without anemia:
indications for treatment
Introduction
lron deficiency (ID) occurs when absorption of dietary 
iron is not sufficient to cover loss of iron and the body’s iron 
requirements. The most severe form of ID is iron deficiency 
anemia (IDA), which develops after depletion of physiologi-
cal iron stores. IDA is the most common nutritional deficiency 
worldwide, occurring in 1.24 billion people, mostly women 
and children in developing countries [1]. The prevalence of iron 
deficiency without anemia (IDWA) is unknown although it has 
been suggested that it can be twice that of IDA [2]. Iron deficien-
cy anemia is due to diets that are poor in bioavailable iron, and 
therefore inadequate to meet iron requirements. This problem 
is particularly important in high-risk groups like women and 
children [3-5]. Those at risk of ID may have one or a combination 
of many risk factor(s) (Table 1).
The benefit of iron supplementation in the treatment of IDA 
is well established and it is clear that wider use of iron supple-
mentation in developing countries to provide bioavailable iron 
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ABSTRACT
Background and Purpose: Iron deficiency without anemia (IDWA) is the predominant form of iron deficiency (ID). In 
IDWA a negative iron balance reduces the iron stores responsible for keeping the hemoglobin concentration stable. The 
medical consequences of IDWA and the need for treatment of the condition are debated. 
Methods: An electronic-based search was performed using the Embase, Ovid Medline and and Cochrane library data-
bases. The following medical subject heading (MeSH) terms, keywords and their combinations were used: “iron deficien-
cy”, “oral iron”,” iron supplements”, “anemia”, “iron deficiency without anemia” and “iron adverse events”.
Results: Mounting evidence suggests that even mild ID (serum ferritin <20-35 ug/L) can result in symptoms such as 
fatigue, altered cognitive functions, decreased aerobic performance, restless legs syndrome, reduced quality of sleep, 
and so on. Individuals, especially from the well-known risk groups such as growing children, menstruating and pregnant 
women, but also endurance athletes and the elderly, frequently develop mild forms of ID. Current evidence strongly 
indicates that to ensure optimal health and development, it is important to prevent and treat even mild ID through iron 
supplementation. Treatment with oral ferrous iron preparations is known to be effective and safe in most patients. Despite 
much progress also with parenteral iron preparations, oral iron therapy is clearly the first-line treatment in all subjects 
with diagnosed ID.
Conclusions: IDWA is an under-recognized, underdiagnosed and certainly undertreated entity. The balance of current ev-
idence strongly indicates that to ensure optimal health and development, it is important to prevent and treat even mild ID.
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Table 1 Iron deficiency: groups of risk factors.
INAPPROPRIATE IRON SUPPLY FROM FOOD ALTERED IRON ABSORPTION INCREASED IRON DEMAND LNCREASED IRON LOSS
• Vegetarian or vegetarian-like diet
•  Eating disorders (anorexia and bulimia 
nervosa)
•  Malnutrition in low socioeconomic status, 
teenagers or elderly




•  Irritable bowel disease (IBD) and 
other intestinal diseases at any age
•  High consumption of iron 
absorption inhibitors (e.g. phytates, 
polyphenols, soy protein, calcium).
• Growth (children)





• Regular blood donation
• Menorrhagia, perimenopause
•  Pathological blood loss: 
gastrointestinal blood loss 
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would have a substantial effect on relieving global ID. 
Recent studies have indicated that anemia per se is less 
important from a public health standpoint than the effects on 
health associated with tissue ID, as ID can have serious conse-
quences (Table 2) [6-11]. In developed countries such as the USA 
and countries in Europe, ID is less frequent and less severe, 
with IDA occurring in 1 to 3% of adult men and post-meno-
pausal women [12,13]. lron deficiency without anemia (IDWA) 
predominates. In this form of ID, a slightly negative iron bal-
ance reduces the body's iron stores but the hemoglobin (Hb) 
concentration remains normal. lron deficiency without anemia 
is perceived to be a less severe, milder form of ID, although 
there are conflicting reports concerning its symptoms. 
In the last 20 years, guidelines for the management of ID 
have been based on the perception that mild ID, such as IDWA, 
may have only subtle health consequences, and on the view 
that preventive iron therapy in risk groups has no important 
clinical benefits in well-nourished populations in developed 
countries, and that widespread iron supplementation could 
even be harmful [14]. However, there is increasing evidence 
that ID both with and without anemia should be treated with 
iron supplementation. In this review the clinical consequenc-




In January 2020, we searched the Embase, Medline and 
Cochrane library databases for potentially relevant publica-
tions, considering all dates from January 2009 to January 2020. 
In order to maximize the number of publications meeting the 
selection criteria, the medical departments of companies mar-
keting oral iron supplements were contacted in order to request 
publications not identified during the electronic search. Ref-
erence lists from studies initially selected and from existing 
reviews were also searched to identify any additional relevant 
studies not identified by the electronic searches. 
Search strategy
The following search terms were used: “iron deficiency”, “oral 
iron”, “iron supplements”, “anemia”, “iron deficiency without 
anemia” and “iron adverse events”. No limits were set in terms 
of study design or dose of oral iron. The search was performed 
for publications in English, French or Spanish. Articles in other 
languages for which a translation was available in one of the 3 
study languages were also included.
Study selection
Titles and abstracts of all the studies retrieved were reviewed 
by a single reviewer (CCB) to initially exclude clearly irrele-
vant publications. Five per cent of the articles excluded at this 
point were reviewed to confirm their irrelevance. 
The abstracts of the remaining articles were re-evaluated and 
any designated for exclusion were reviewed and confirmed by 
a second reviewer (LQ). The full text of each article selected 
was obtained and reviewed by the two reviewers to ensure the 
article met the inclusion criteria. Discrepancies were resolved 
by consensus or consultation with a third part if no agreement 
could be reached.
Eligibility criteria and data extraction
Publications were included if the full text of the article was 
available and data were clearly reported. All types of clinical 
studies were included.
For each study included, one reviewer extracted the data and 
the second reviewer confirmed the selected data. Any potential 
discrepancies were resolved by consensus and, if necessary, by 
consulting a third reviewer.
Statistical analysis
A descriptive analysis of the data obtained was performed.
Results
Medical consequences of IDWA
The evidence indicates that even mild ID (serum ferritin <20-
35 ug/L) can result in symptoms such as fatigue, altered cog-
nitive functions, decreased aerobic performance, restless legs 
syndrome and reduced quality of sleep [15-18].
Symptoms that may be related to IDWA, such as lowered phys-
ical work capacity or mental changes diagnosed by general 
practitioners, are not always specific (Table 3) [10,15-22,24-26]. 
The relationship with IDWA is therefore best analyzed accord-
ing to changes in symptoms after double-blind treatments with 
iron and placebo over a sufficiently long period. Several inter-
vention studies have been performed in subjects with IDWA 
(Table 4) [10,18-20, 22-26]. 
Table 2 Consequences of iron deficiency.
CONSEQUENCES REFERENCE
Increased frequency of low birth weight Cogswell et al. (2003) [6]
Increased frequency of prematurity Stoltzfus et al. (2003) [7]
Increased frequency of perinatal mortality in pregnancy Little et al. (2005) [8]
Impairment in psychomotor development and cognitive function in infants and preschoolers Lozoff et al. (2006) [9]
Decreased cognitive performance in adolescents Bruner et al. (1996) [10]
Deficit in work performance in adults Stoltzfus et al. (2001) [11]
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Physical capacity in subjects with IDWA
It is well known that aerobic performance capacity in athletes 
is reduced in IDA because of a decrease in total Hb mass, 
which causes insufficient oxygen transport to peripheral tissues 
[23]. However, there is controversy over whether IDWA limits 
performance in sport. Three recently published randomized, 
placebo-controlled studies provide evidence that performance 
is impaired if iron stores are depleted while Hb remains with-
in the normal range (Table 4). In a study by Hinton et al. [24] 
iron-depleted non-anemic women received 10 mg of elemen-
tal iron or placebo twice daily for 6 weeks. After 2 weeks of 
treatment, endurance training was initiated in these physically 
active, but untrained women. After 4 weeks of endurance train-
ing, the time to complete a 15-km time trial was found to have 
improved twice as much in the iron-treated women as in those 
receiving placebo. After 6 weeks of iron treatment, ferritin was 
significantly increased and soluble transferrin receptor (sTfR) 
significantly decreased, while these measures remained un-
changed in the placebo group. Hb and maximal oxygen uptake 
(VO2max) did not change in either group. 
Table 3 Symptoms of iron deficiency without anemia.
Table 4 Results of double-blinded studies conducted in subjects with iron deficiency without anemia.
SYMPTOMS REFERENCE
Fatigue Verdon et al. (2003) [20], Patterson et al. 2000 [21], Patterson et al. (2001) [22]
Altered cognitive functions (lack of concentration/loss memory) Bruner et al. (1996) [10]
Decreased aerobic performance and/or increased muscle fatigability Hinton et al. (2000) [24], Friedmann et al. 2000 [25], Brutsaert et al. (2003) [26]
Depressive mood, anxiety/mental health Verdon et al. (2003) [20], Patterson et al. 2000 [21], Patterson et al. (2001) [22]
Thermoregulation disorders (feeling cold, hot flashes) Rosenzweig et al. (1999) [15]
Hair and nail alterations Trost et al. (2006) [16]
Restless leg syndrome Earley (2003) [17]
Reduced quality of sleep Lee at al. (2001) [18]
Immune system alteration Ahluwalia et al. (2004) [19]
AUTHOR
(year) (ref) N PATIENTS TREATMENT TEST CRITERION RESULTS









Better 15 km time
Friedmann et al. 









Increase in aerobic 
capacity
Brutsaert et al. 
(2001) (28) 20 (10 vs 10) Young women
6 weeks
Fe (II) 10 mg/day
Serum ferritin
Knee-extension






Bruner et al. 




Fe (II) 260 mg/day or placebo
Serum ferritin
4 cognitive functioning 
test scores
12.1→27.3 μg/L
Better verbal learning 
and memory
Krafft et al. 
(2004) (24) 52 (28 vs 24) Women postpartum
12 weeks
Fe (II) 80 mg/day or placebo Serum ferritin
16.1→47.6 μg/L vs
19.0→24.0 μg/L





a) Fe (II) 105 mg/day
b) Meat rich diet
Serum ferritin




Verdon et al. 




Fe (II) 80 mg/day or placebo
Unexplained fatigue, 
10 point visual 
analogue scale
Iron group: decrease
in level of fatigue
Brownlie et al. 
(2002) (25) 41 Women
6 weeks




IDWA impairs aerobic 
adaptation, this can be 
corrected by iron




Iron deficient group: 
ferritin 13 μg/L (n=12) vs
Iron sufficient group: 
ferritin 96 μg/L (n=49
Imapaired immune 
function 
(T cell proliferation 
upon stimulation)
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In a study by Friedmann et al. [25], 40 young elite non-ane-
mic athletes drawn from a variety of sports (23 females, 17 
males) and showing low ferritin were recruited and random-
ly assigned to an iron-treatment or a placebo group. For 12 
weeks, while the athletes continued with their usual training 
program, they received either elemental iron 100 mg or pla-
cebo twice a day. Ferritin levels increased significantly only 
in the iron-treated group, while Hb concentration and total 
Hb mass did not change in either group. After iron repletion, 
VO2max was significantly increased; furthermore, performance 
in a highly intensive treadmill run, which caused exhaustion 
within 2 to 4 minutes, was also significantly and even more im-
pressively enhanced, due to improved aerobic capacity, in the 
subjects receiving iron. In an investigation by Brutsaert et al. 
[26], 20 iron-depleted non-anemic untrained women were treated 
with 10 mg of elemental iron or with placebo twice a day for 6 
weeks. In the iron-supplemented group, significantly improved 
fatigue resistance in dynamic leg extension exercise was ob-
served, whereas no changes in Hb or ferritin values occurred, 
although transferrin saturation rose significantly. 
Effects of IDWA on pregnancy and lactation
There are no clear data concerning IDWA during pregnancy 
and lactation and its relationship with feto-maternal morbidity. 
However, it is known that during pregnancy, early ID (first tri-
mester) without anemia will result in anemia beginning around 
the second trimester (maximal red cell expansion) if no supple-
ments are given [27]. In other words, preconceptional ID is a ma-
jor risk factor for developing anemia in pregnancy and for its 
numerous negative effects. Iron requirements during pregnan-
cy are double those of the pre-pregnancy period, due not only 
to the red blood expansion, but also to the fetal and placental 
development [28]. lt is known that neonates of woman with low 
or empty iron stores at term have lower iron stores during ne-
onatal growth and adolescence. Iron supplementation should 
be routinely indicated during pregnancy unless iron stores of 
about 500mg (serum ferritin >70ug/L) are present at the be-
ginning of pregnancy (achieved by approximately 15-20% of 
women in Western countries) [28]. The benefits of iron supple-
mentation postpartum are indicated in a study by Krafft et al. 
[29]. Lactating women with low iron stores show lower iron 
transfer to the milk. Furthermore, ID in early pregnancy causes 
increased placental angiogenesis, which results in a so-called 
feto-placental miss ratio, an underlying cause of diseases after 
birth (fetal programming) [30]. Currently, other consequences of 
pure ID during pregnancy and lactation on mothers' physical or 
mental performance are poorly investigated [31]. 
Fatigue and mental and somatic health and their 
relationship with iron deficiency
Fatigue is an unspecific symptom, responsive to iron therapy, 
that has been documented for more than 150 years [17,20,22, 32,33]. 
In a study by Verdon et al., 144 non-anemic women aged 18-
55 years (mean serum ferritin 30 μg/L) received either 80 mg 
Fe(II)/day or placebo for four weeks [20]. The level of fatigue 
decreased significantly in the iron-treated group. A subgroup 
analysis showed that only women with ferritin <50 μg/L im-
proved with oral supplementation. In a study conducted in Aus-
tralia, 44 women with IDWA (serum ferritin <20 μg/L) were 
randomly allocated to either iron supplementation or a high-
iron diet for 12 weeks (Table 4) [22]. Mental health and vitality 
scores increased in both intervention groups; ferritin increased 
more under iron supplementation. 
The possible relationship between IDWA and mental and 
somatic health symptoms like anger or fatigue were studied by 
Sawada et al. [34] in a group of young Japanese young women 
(18-22 years). These authors concluded that fatigability, anger 
and tension were significantly higher in IDWA subjects than in 
normal subjects. These women also showed a higher propor-
tion of neurotic tendencies. These findings may suggest that 
IDWA could be a risk factor for the development of anger or 
fatigue in young women [34]. In all these studies, various pa-
rameters of physical or mental health were clearly connected 
with IDWA. It is particularly worth noting that some of these 
unspecific symptoms improved after treatment with oral iron.
The immune system is related to iron status
Another critical function that could be impaired in mildly 
iron-deficient individuals is immune function. In a study by 
Ahluwalia et al. [19], 72 homebound, elderly, apparently healthy 
women provided blood for comprehensive evaluation of iron 
status and cell-mediated and innate immunity. Women were 
classified as iron deficient on the basis of multiple abnormal 
iron status test results. In iron-deficient women, T cell prolifer-
ation upon stimulation with concanavalin A and phytohemag-
glutinin A amounted to only 40-50% of that found in iron-suf-
ficient women. lt was concluded that ID is associated with 
impairments in cell-mediated and innate immunity and may 
render older adults more vulnerable to infections. 
Treatment options
There is good evidence suggesting that every case diag-
nosed with ID, especially symptomatic patients, should be ad-
equately treated with iron, even in the absence of anemia [35] 
(Figure 1). The treatment should always be initiated following 
medical consultation, and every severe case of ID should be 
regarded as a serious clinical symptom that requires diagnostic 
evaluation of the underlying disease. Because daily iron loss in 
adults is in the range of 1-2 mg/day, moderate to severe IDA 
resulting in a deficit of 1000 to 2500 mg iron is, in most cases, 
due to abnormal blood loss (hypermenorrhea or gastrointestinal 
bleeding) [14]. Therefore, in all these patients, a complete gastro-
intestinal evaluation including colonoscopy and gastroduoden-
oscopy should be obligatory. 
In IDWA (Hb 12 g/dl; serum ferritin >12 μg/L), as dis-
cussed above, there are good arguments for treatment with oral 
iron for at least 3 months in order to replete the iron stores 
completely, i.e. to reach a serum ferritin value of ideally >50 
μg/L. The lower cut-off value of serum ferritin for intervention 
with iron supplementation is less well defined. Some authors 
hesitated to give iron to individuals with serum ferritin <20 
μg/L. Others take <35 μg/L or, in the elderly even <50 μg/L, as 
an indication of partly depleted iron stores which are already 
having physiological consequences [20]. 
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Treatment with oral ferrous iron preparations is known to 
be effective and safe in most patients. Despite much progress 
also with parenteral iron preparations, oral iron therapy is 
clearly the first-line treatment in all subjects with diagnosed ID, 
because of safety aspects. Among oral iron preparations, the 
use of any ferrous salt (mostly ferrous sulfate) is generally rec-
ommended in the literature, albeit without much discussion of 
the relevance of the bioavailability of a given pharmaceutical 
iron preparation. Interestingly, this type of preparation has been 
studied in detail in some countries with some significant results 
[36-39]: i) all ferric iron preparations tested so far, even including 
ferric hydroxide polymaltose, a market leader in some coun-
tries, have only very limited bioavailability; and ii) there are 
considerable differences between ferrous preparations [38]. Dif-
ferences in bioavailability are linked to the limited solubility 
and absorbability of iron in the duodenum and upper jejunum, 
the complex chemistry of iron at neutral pH, and the strong in-
fluence of the galenic composition of the respective drug. The 
bioavailability of any pharmaceutical iron preparation should 
therefore be documented and only iron preparations that are 
highly effective and safe should be used as iron supplements. 
The efficacy and also the frequency of side effects depend 
upon the administered daily dose and the application modus. 
In adults, a typical dose of 60-100 mg/day Fe is normally suf-
ficient to increase the Hb concentration by 0.2-0.3 g/dl/day in a 
non-bleeding anemic patients [27, 38- 40]. In patients with substan-
tial blood loss (hypermenorrhea, gastrointestinal blood loss), 
up to 200 mg of elemental iron/day in 2-4 fractions is possible 
without serious side effects [41]. The best bioavailability is found 
when iron is taken on an empty stomach together with water. 
This can be stabilized by combination with fruit juice (ascorbic 
acid), whereas the use of tea, milk, cola, coffee or cereals should 
be avoided as these contain substances that act as inhibitors of 
iron absorption [42-44]. lf administered together with a meal, iron 
supplements may be better tolerated in some individuals, but at 
the cost of substantially decreased bioavailability [42]. 
Parenteral iron therapy is occasionally necessary and help-
ful in patients who are intolerant of or unresponsive to oral iron 
therapy, in patients with “functional ID” due to recombinant 
erythropoietin therapy, or in cancer patients [45]. One particu-
lar consideration arises in relation to its use in patients with 
inflammatory bowel disease, in which oral iron seems to in-
teract with affected cells in the intestinal tract. In patients with 
Crohn's disease or ulcerative colitis, it has been shown that oral 
ferrous fumarate, but not intravenous iron sucrose, increased 
clinical disease activity [46].
Three parenteral iron products are available: iron dextran, 
ferric gluconate and iron sucrose. lron dextran administration is 
associated with a high incidence of adverse reactions including 
anaphylaxis and death [47]. The newer formulations are better 
tolerated, although serious side effects have been reported with 
ferric gluconate, whereas recommended doses of iron sucrose 
appear very safe with little risk of anaphylactic reactions [48-51]. 
These data were collected during short-term acute treatments, 
and although parenteral iron achieves seemingly favorable 
short-term results, there are no data to support its safety in the 
long term. However, there are reasons to suggest possible iron 
overload with chronic use [52]. 
Oral iron does induce side effects, which mainly affect the 
gastrointestinal tract; approximately 10-20% of treated indi-
viduals discontinue iron supplementation due to side effects. 
Gastrointestinal symptoms include nausea, vomiting, epigas-
tric pain, eructation, pyrosis, meteorism, colic pain, flatulence, 
constipation, thin feces or diarrhea [53,54]. Whereas individuals 
with severe IDA may refuse to take any kind or oral iron prepa-
ration due to side effects, the majority of individuals have only 
mild problems [54]. A systematic review published in 2013 eval-
uated the tolerability of several iron supplements based on data 
obtained in publications. Extended-release ferrous sulfate with 
mucoproteose appeared to be the best tolerated of the different 
oral iron supplements [55].
Is there a risk from iron medication?
The widespread use of iron prophylaxis in countries with 
a high prevalence of severe IDA is effective, although it can 
also have adverse effects under certain conditions [56]. A recent 
community-based study in children in Zanzibar indicated that 
iron supplementation without restriction to iron-deficient sub-
jects may be associated with increased risk of hospitalization 
and mortality due to malaria [57]. Plasmodium falciparum has 
been shown in in vitro studies to be less efficient in infect-
ing iron-deficient erythrocytes than iron-replete erythrocytes, 
which suggests that ID may have a protective effect against 
malaria infection [58].
Iron deficiency without anemia
Risk group for iron deciency
Hb, serum ferritin (sTfR)
IDA (Hb < 12 g/dL
Serum ferritin < 12 μg/L)
IDWA (Hb ≥ 12 g/dL)
Serum ferritin ≥ 12 μg/L


















iron (iron sucrose i.v.)
NO
Figure 1 Algorithm for treatment of iron deficiency.
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The most frequent argument against iron supplementation 
in individual subjects concerns the theoretical risk of chron-
ic toxicity of iron as a reactive transition heavy metal. With 
regard to the treatment of athletes with iron, for example, a 
critical review underlined an important rule: “first do no harm” 
[59]. However, this argument is sometimes used without enough 
detailed thought and discussion.
lt is clear that any indiscriminate iron supplementation 
carries the risk of inducing clinically relevant iron overload in 
individuals homozygous (Northern European descent, preva-
lence, 1:200) or heterozygous (1:10) for the C282Y allele of 
the HFE gene [60]. However, these subjects show increased and 
not decreased serum iron and serum ferritin values, and can 
easily be distinguished from subjects with IDWA. The question 
of whether non-indicated, prolonged (up to years), high-dose 
(60-100 mg/day) oral iron treatment can or cannot induce iron 
overload in an individual with a normal iron regulation system 
is debated in the literature. In theory, the formation of exces-
sive storage iron should stimulate hepcidin synthesis in the liv-
er, which should then inhibit intestinal iron absorption. There 
are some case reports available in the literature that describe 
substantial liver siderosis after prolonged oral iron intake [61,62]. 
However, this was before HFE and the hepcidin era and the 
presence of a genetic hemochromatosis was not excluded. lt 
should also be emphasized that in this situation, a high ferri-
tin value (>300 μg/L) would be a clear sign of misuse of iron 
treatment. 
Another important question is to what degree is iron loading 
is harmful? We can learn from iron overload diseases that the 
degree of excessive whole-body iron storage is correlated with 
the severity of organ damage in the liver, pancreas and heart. 
The situation in the liver is studied in the most detail. In hemo-
chromatosis and in post-transfusional siderosis, progression of 
hepatic fibrosis has been observed for liver iron concentrations 
>22.3 mg per g [62], and >16 mg/g dry weight [63], respectively. 
With gene testing available in hemochromatosis it became ob-
vious that most diagnosed patients are moderately iron loaded 
but have mild or even no clinical symptoms [64,65], which at least 
indicates that moderately increased storage iron is not extreme-
ly risky in humans. Nevertheless, many publications still favor 
the “iron hypothesis”, which suggests a fundamental role of 
even mildly increased iron in the development and progression 
of atherosclerosis or cancer [66,67]. However, it should be point-
ed out that neither cardiovascular nor tumor diseases (except 
hepatoma in cases with liver cirrhosis) are more pronounced 
in patients with clinical hemochromatosis and very severe iron 
overload [59,68]. As found in the famous Salonen publication [69] 
there is a correlation between high ferritin values and the risk of 
heart infarction, but here ferritin acts as an acute phase protein 
in a disease state and not as an indicator of iron overload [70,71]. 
In conclusion, when iron is used and carefully monitored in 
individuals with ID, the “iron hypothesis” should not be rele-
vant. This is shown in Figure 2 with a u-type risk profile. The 
goal is to normalize the body’s iron stores in both respects. The 
high risk on the right side of the figure with very severe iron 
overload should not be a reason for neglecting the risk of ID on 
the left side, which should be treated with the appropriate iron 
formulation.
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 IRON DEFICIENCY
 Anemia Without Anemia
Hb < 12g/dL  >12g/dL
Serum ferritin < 12μg/L >5 and <35 μg/L
 IRON OVERLOAD 
 Serum ferritin > 1000μg/L 
 Liver Fe >2mg/g dry weight
 Tfs NTBI increased
 Tfs-Transferrin saturation
 NTBI - Non-transferrin-bound iron
Cardiac problems In severe cases:












Normal iron stores - Serum ferritin 35-200μg/L
Figure 2 Risk of different clinical complaints according to iron stores.
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Conclusions and perspectives
IDWA is an under-recognised, underdiagnosed and certain-
ly undertreated entity. The balance of current evidence strongly 
indicates that to ensure optimal health and development, it is 
important to prevent and treat even mild ID not only in growing 
individuals and menstruating and pregnant women, but also in 
endurance athletes and the elderly. 
Considering the ingenious systems available that control 
the absorption and metabolism of iron, it is paradoxical that 
ID is still the most common deficiency disorder in the world 
and the main remaining deficiency in the developed world. A 
reasonable explanation may be the marked changes that have 
occurred in human nutrition. The current low-energy lifestyle 
has further led to a situation where the risk of nutrient defi-
ciencies, especially ID, have increased. IDWA is not easy to 
diagnose, and any chosen cut-off value of diagnostic param-
eters of iron status (serum ferritin, sTfR) will have either low 
specificity or low sensitivity. Serum ferritin remains the diag-
nostic gold standard in practice. Values below 20-35 μg/L make 
ID the most likely diagnosis and do at the same time exclude 
substantial iron overload. lt is therefore very important in prac-
tice that iron supplementation is always based on actual serum 
ferritin values in order to prevent inappropriate doses from be-
ing administered. Bearing this in mind, all the risk profiles for 
inducing iron overload by iron supplementation are irrelevant. 
Several intervention studies show that iron supplementation in 
subjects with IDWA is effective and helpful for the patient. It 
may also prove cost-effective for the healthcare system, as fur-
ther diagnostic costs are minimized. Nevertheless, parallel to 
iron supplementation, the cause of IDWA should be carefully 
explored. Faced with a patient outside a classical risk group for 
ID, the possibility of occult blood loss should always be related 
to the development of ID. lron deficiency without anemia could 
be a transient stage to severe ID, in which a complete gastro-
intestinal workup is necessary in order to find the reason. The 
first-line treatment of ID is oral treatment using a pharmaceu-
tical ferrous iron preparation with documented high bioavail-
ability. Repletion of exhausted iron stores using a 60-100 mg 
dose of ferrous iron (Fe(ll))/day on an empty stomach can take 
up to 3 months. Retesting serum ferritin (>50 μg/L) can doc-
ument the therapeutic success. Treatment failure is caused by 
low compliance (e.g. side effects), the wrong iron compound 
(e.g. low bioavailability), or a suboptimal administration mo-
dus (e.g. consumed with iron-chelating food ingredients).
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